Neuroendocrine Neoplasms of the Female Genitourinary Tract: A Comprehensive Overview
, Sai Swarupa Vulasala 1,*, Dheeraj Gopireddy 1, Ajaykumar C. Morani 2, Taher Daoud 2, Rebecca Waters 2 and Priya Bhosale 2
Round 1
Reviewer 1 Report
Thank you for a well-written review.
Only few comments
Line 42: I would erase pheochromocytoma - as there are no renal phenochromocytomas.
Libe 174: The line "Renal NEN exhibits improved survival rates than poorly differentiated renal NEN 174 (3).". Maybe that sentence needs a rephrasing?
3. Page 12, line 329. Survival rates 8-40%? Is that after one year, five years? Please add the time where these survival rates are seen.
Author Response
- Line 42: I would erase pheochromocytoma - as there are no renal pheochromocytomas.
Response: Thank you. We acknowledged and erased the term pheochromocytoma in the line. 42.
2016 WHO classification of renal tumors classified renal neuroendocrine neoplasms into well-differentiated NET, small-cell NEC, and large-cell NEC (Table 1) [4].
- Libe 174: The line "Renal NEN exhibits improved survival rates than poorly differentiated renal NEN 174 (3).". Maybe that sentence needs a rephrasing?
Response: Thank you. We rephrased the sentence.
Renal NEN has higher survival rates than poorly differentiated renal NEN [3].
- Page 12, line 329. Survival rates 8-40%? Is that after one year, five years? Please add the time where these survival rates are seen.
Response: Thank you. We included the time for the survival rates.
The stage is the most important prognostic factor in small-cell NEC, with 5-year survival rates ranging from 8-16% in low-to-high stage disease (Figure 11) [66,93,99].
Reviewer 2 Report
The authors have compiled a comprehensive review using information from 120 citations. The manuscript reads well and is structured clearly.
A couple minor recommendations for the authors to enhance the quality of the manuscript:
- The authors recommend AJCC based staging for the tumor types. It would be beneficial to also discuss FIGO staging for site-specific tumors.
- A few treatment algorithm figures illustrate to observe in specific scenarios. Please explain/elaborate case follow-up timeline in the case of "observe".
A very minor suggestion for the treatment algorithm flowchart (not a mandatory change required for acceptance) : look into flowchart creation specific tooling for better styling/decision points etc. An example online tool is Lucidchart.
Author Response
- The authors recommend AJCC-based staging for the tumor types. It would be beneficial to also discuss FIGO staging for site-specific tumors.
Response: Thank you for the comment. We included the updated AJCC staging of the genitourinary tumors.
- A few treatment algorithm figures illustrate to observe in specific scenarios. Please explain/elaborate case follow-up timeline in the case of "observe".
Response: Thank you. We included the timeline for the surveillance in the revised manuscript.
Follow-up surveillance with the US or CT once every 6 months during the first year, once in a year during the first three years, and once every 2 years thereafter.
- A very minor suggestion for the treatment algorithm flowchart (not a mandatory change required for acceptance: look into flowchart creation specific tooling for better styling/decision points etc. An example online tool is Lucidchart.
Response: Thank you. We utilized the Lucidchart tool to construct flowcharts in the revised manuscript.
